SOBI gains rights to distribute Ravicti in Middle East

1 October 2013

Swedish Orphan Biovitrum (STO: SOBI) says USA-based Hyperion Therapeutics (Nasdaq: HPTX) has granted the company exclusive rights to distribute its Ravicti (glycerol phenylbutyrate) oral liquid on a named patient basis for the chronic treatment of urea cycle disorders (UCD) in the Middle East.

Under the agreement, SOBI receives the rights to provide Ravicti in Saudi Arabia, Oman, United Arab Emirates, Jordan, Kuwait, Qatar and Bahrain. Financial details were not disclosed.

"We are proud of this partnership with Hyperion and Ravicti is a perfect fit with our existing UCD business and the capabilities within our Genetics Therapeutic Area," said Geoffrey McDonough, president and chief executive at SOBI, adding: "We believe the recent FDA approval of Ravicti can allow us to provide access for this important therapy in the Middle East."

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK